ACTRN12620000726954已完成未知
Open-label Trial to Investigate The Efficacy and Safety of Focused Extracorporeal Shockwave Therapy on Knee Osteoarthritis related Bone Marrow Oedema.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •Individuals with medically diagnosed painful knee osteoarthritis (OA) (VAS =>4 out 10) will be screened for suitability by a consultant rheumatologist according to the American College of Rheumatology (ACR) clinical classification criteria for knee OA.
排除标准
- •History of neurological disorders affecting sensory, motor or cognitive function; recent lower limb injury or surgery; previous treatment with ESWT or intra-articular injection into the affected knee during the last 6 months.
研究者
相似试验
未知
3 期
An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/r/ABT-267 Co-administered With Ribavirin for 12 or 16 Weeks in Treatment-Naive and Treatment-Experienced Japanese Adults With Genotype 2 Chronic HCV Infection With and Without Compensated Cirrhosis (GIFT-II)JPRN-jRCT2080222382AbbVie GK
招募中
3 期
Phase 3 study to Evaluate the Efficacy and Safety of Avatrombopag in Japanese Adults with Chronic Immune ThrombocytopeniaChronic Immune ThrombocytopeniaJPRN-jRCT2031220005Shimizu Yasuko19
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-DKF. Hoffmann-La Roche Ltd680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-ITF. HOFFMANN - LA ROCHE LTD.680
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2015-005597-38-IEF. Hoffmann-La Roche Ltd680